Leo Pharma on leaving 22 markets: Freeing up resources enables us to invest in unmet drug needs
”We are dedicated to always putting the patient first,” states Leo Pharma’s CSR strategy, but how does add up to the firm’s exiting 22 of its 80 markets? According to EVP Becki Morison, it’s still all about the patient.
by Christian Bundgaard & Christopher Due Karlsson, translated by daniel pedersen
Like most companies of a certain size, Leo Pharma has a corporate social responsibility strategy, CSR, purposed with throwing light on how the firm is integrating societal concerns into its practices and policies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma pulls the plug on Leo Innovation Lab
For subscribers
Leo Pharma to withdraw from a quarter of its markets
For subscribers
